Results From the Phase 3 GCIG INTERLACE Study
The phase 3 GCIG INTERLACE study, presented by Dr. Mary McCormack at the 2023 ESMO Congress, has revealed a significant improvement in progression-free and overall survival rates among patients with advanced cervical cancer. The addition of a short course of induction chemotherapy to standard-of-care chemoradiation has been identified as a potential new standard of care.
- The study randomized 500 patients between standard-of-care chemoradiation and the same standard of care preceded by 6 weeks of carboplatin and paclitaxel chemotherapy.
- There was no gap between the chemotherapy and the start of radiation.
- In the standard-of-care arm, 64% of women were alive and free of disease at 5 years.
- In the experimental arm with the additional chemotherapy, 74% were alive without evidence of disease recurrence at 5 years.
- The 5-year overall survival with locally advanced disease improved from 72% to 80% with the addition of chemotherapy.
…with the additional 6 weeks of chemotherapy, we found that the 5-year survival is boosted to 80%. This is also a tremendous improvement, and it’s probably the biggest shift that we’ve seen in outcome in this disease in over 20 years.
— Mary McCormack, MD, University College London Hospital, United Kingdom
More on Cervical Cancer